


Approved prescription drug products with therapeutic equivalence evaluations.

[Washington, D.C.?] : U.S. Dept. of Health and Human Services, Public Health Service, Food and Drug Administration, Bureau of Drugs : 1980-

<http://hdl.handle.net/2027/mdp.39015072933016>

HathiTrust



www.hathitrust.org

Public Domain, Google-digitized

http://www.hathitrust.org/access_use#pd-google

We have determined this work to be in the public domain, meaning that it is not subject to copyright. Users are free to copy, use, and redistribute the work in part or in whole. It is possible that current copyright holders, heirs or the estate of the authors of individual portions of the work, such as illustrations or photographs, assert copyrights over these portions. Depending on the nature of subsequent use that is made, additional rights may need to be obtained independently of anything we can address. The digital images and OCR of this work were produced by Google, Inc. (indicated by a watermark on each page in the PageTurner). Google requests that the images and OCR not be re-hosted, redistributed or used commercially. The images are provided for educational, scholarly, non-commercial purposes.

HE 20.9210:105/supp. 9

477-R-3

Pharm.
~~RM~~
~~300~~
~~1A653~~


4th ed.
Suppl. 9

REFERENCE

The University
of Michigan
Pharmacy
Library

**CUMULATIVE
SUPPLEMENT 9
AUG'83 - MAY'84**

SERIAL



APPROVED PRESCRIPTION DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

4TH EDITION

REFERENCE
DOES NOT CIRCULATE

UNIVERSITY OF MICHIGAN
LIBRARIES

JUL 26 1984

DEPOSITED BY THE
UNITED STATES OF AMERICA

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUGS AND BIOLOGICS

Digitized by Google

Original from
UNIVERSITY OF MICHIGAN

FOOD AND DRUG ADMINISTRATION
APPROVED PRESCRIPTION DRUG PRODUCTS
WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS
CUMULATIVE SUPPLEMENT

I. PREFACE

This cumulative supplement is one of a series of monthly updates to the Approved Prescription Drug Products with Therapeutic Equivalence Evaluations, 4th Edition (the List), to cover interim revisions to the annual publication of the List in its entirety. The List is comprised of several parts and some by their nature, are identified by the term "list". The cumulative supplements routinely provide updates to two of these lists: The Drug Product List and the DESI Addendum.

The List cannot be used effectively without the current cumulative supplement. Users may wish to place an asterisk (*) in the list to the left of the ingredient(s) in the Drug Product List and the product name in the Addendum to indicate that changes to that entry appear in the cumulative supplement. It is also suggested that earlier cumulative supplements be discarded to avoid possible confusion. In this way, only the List and current cumulative supplement need be referenced.

A. DRUG PRODUCT LIST

The Drug Product List cumulative supplements include the changes made since August 1, 1983. Each subsequent cumulative supplement replaces the previous month's cumulative supplement.

Information in this cumulative supplement follows the format of the Drug Product List. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Context information on drug products is provided in each cumulative supplement for completeness to assist in locating the proper place in the Drug Product List for the revision. (Strength(s) which already exist in the publication will not be repeated for context.) A page number in parentheses referring to the Drug Product List is located to the right of the ingredient(s).

Additions to the Drug Product List are indicated by new information in the cumulative supplement. Additions new to the current cumulative supplement are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is dropped in subsequent cumulative supplements for that item.

Deletions from the Drug Product List are indicated by overstruck print in the cumulative supplement. Deletions new to the current cumulative supplement are indicated by the symbol >DLI> (DELETE) to the left of the line containing the overstruck print. The >DLI> symbol is dropped in subsequent cumulative supplements for that item.

A newly approved product is identified by the lozenge (⌘) to the right of its strength. This identifier remains throughout all cumulative supplements for this edition.

B. ADDENDUM: DESI Pending List

Information in this cumulative supplement follows the format of the Addendum. Additions and deletions are indicated in the same manner as in the cumulative supplement to the Drug Product List. A change in Current Status of a DESI product is also indicated by an addition and a deletion.

II. SPECIAL NOTES

A. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

Categories of counts derived from product information in the Drug Product List and from this cumulative supplement are presented. The report includes counts of new molecular entities approved by the agency during the current month.

B. PRODUCTS CONTAINING PHENACEIIN

The October 5, 1983, Federal Register (48FR45466) provides the following Summary: "The Food and Drug Administration (FDA) is withdrawing approval of new drug applications or parts of new drug applications that provide for drug products containing phenacetin, except for those drug products that are the subject of a hearing request. The basis of the withdrawal is phenacetin's high potential for misuse and its unfavorable benefit-to-risk ratio when incorporated in analgesic combinations which are then subject to excessive chronic use." The effective date of this withdrawal order is November 4, 1983.

Because the subject products are no longer approved, the cumulative supplement has identified them by deleting the applicable active ingredient headers followed by a reference to this Special Note.

C. THEOPHYLLINE CONTROLLED RELEASE

Two controlled released theophylline tablets are listed as therapeutically equivalent (AB). Because one of these products was recently approved for once-daily dosing, it is important to be aware that the therapeutic equivalence rating was made on the basis of 12-hour dosing intervals. The rating does not apply to once-daily dosing. To date, no data have been submitted upon which the Agency can base a therapeutic equivalence determination among any of the approved theophylline controlled-release products when dosed once-daily.

D. APPLICANT (NAME) CHANGES

Because it is not practical to identify in the cumulative supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this Special Notes section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the cumulative supplement. The current list of applicant holder changes follows.

APPLICANT (NAME) CHANGES

<u>Former Applicant (Name)</u>	<u>New Applicant (Name)</u>	<u>New Abbreviated Name</u>
STERI-MED INC SUB KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
KETCHUM LABORATORIES INC	QUANTUM PHARMICS LTD	QUANTUM PHARMICS
PROFESSIONAL PHARMACAL DIV STERI-MED INC	OPTOPICS LABORATORIES CORP	OPTOPICS PHARMICS
MPL INC SOLOPAK DIV	SOLOPAK LABORATORIES	SOLOPAK LABORATORIES

The reader should consult the above cumulative list each month to become aware of such transfers and changes. By referring to the Applicant Index in the 4th Edition of the APDP, the transferred products can be identified. The reader might wish to flag these products in the List as a reminder that the applicant has been changed.

III. REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

DESCRIPTION OF REPORT

The following report provides summary counts derived from product information in the Drug Product List and the current cumulative supplement. The counts appear in two sections. Section A. refers to the products in the List and Section B. to products in the current cumulative supplement. A new column of data will appear in Section A. each three-month period following July '83. Section A. therefore will provide baseline and quarterly data while Section B. provides monthly activity.

USE OF REPORT

From the data presented under Section B., users should be able to observe such things as (1) newly approved, DESI effective and remarketed drug products which are added to the list; (2) products that are being removed, from the list as the result of withdrawal of approval, changes from prescription to over-the-counter status and discontinued marketing of products; and, (3) trends in approval of products as either multi-source or single source during each month within the quarter. The report does not reflect category changes from multi-source to single source and vice versa. However, the net gain that results from all additions, deletions and category changes is reflected in the quarterly counts for multi-source and single source products.

Drug Product Definition

For this report, a drug product is the representation in the Drug Product List of an active moiety (includes molecular entity and its salts, esters and derivatives) either as a single entity or as a combination product, provided in a specific dosage form and strength for a given route of administration marketed by a firm under a particular generic or trade name.

New Molecular Entity

The active moiety has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or part of a combination.

Drug Product Count

This report provides counts in several categories from the list composed of domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Counts of products still pending in the DESI review are not provided. Excluded also are those approved drug products marketed by distributors; those marketed solely abroad; and products now regarded as medical devices, biologics or foods. Also not included in the counts are those duplicate products of a given applicant whose only distinguishing characteristics are items such as package size, inactive ingredient(s), color and alternate manufacturing sites. These various counts are excluded because the Drug Product List itself excludes products from these categories.

REPORT OF COUNTS FOR THE DRUG PRODUCT LIST

A. COUNTS CUMULATIVE BY QUARTERS

<u>CATEGORIES COUNTED</u>	<u>JULY '83 (BASELINE)</u>	<u>OCT '83</u>	<u>JAN '84</u>	<u>APR '84</u>
DRUG PRODUCTS LISTED	6679	6783	6854	6938
SINGLE SOURCE	1908 (28.6%)	1915 (28.2%)	1933 (28.2%)	1940 (28.0%)
MULTISOURCE ⁽¹⁾	4771 (71.4%)	4868 (71.8%)	4921 (71.8%)	4998 (72.0%)
THERAPEUTICALLY EQUIVALENT	3804 (57.0%)	3891 (57.4%)	3939 (57.5%)	4014 (57.9%)
NOT THERAPEUTICALLY EQUIVALENT	957 (14.3%)	967 (14.3%)	972 (14.2%)	974 (14.0%)
EXCEPTIONS ⁽²⁾	10 (0.1%)	10 (0.1%)	10 (0.1%)	10 (0.1%)
NEW MOLECULAR ENTITIES APPROVED	-	2	8	9
NUMBER OF APPLICANTS	304	310	312	313

B. ACTIVITY FOR SUPPLEMENT NUMBER 9

	<u>MAY '84</u>	<u>CUMULATIVE</u>
DRUG PRODUCTS ADDED:	52	52
NEWLY APPROVED	52	52
DESI EFFECTIVE	0	0
REMARKETED	0	0
DRUG PRODUCTS REMOVED:	14	14
WITHDRAWN APPROVAL	0	0
RX TO OTC SWITCH	0	0
DISCONTINUED MARKETING	14	14
NET GAIN IN DRUG PRODUCTS	38	38
SINGLE SOURCE PRODUCTS APPROVED	18	18
MULTISOURCE DRUG PRODUCTS APPROVED	34	34
NEW MOLECULAR ENTITIES APPROVED:	5	5
AS THE ENTITY-	3	3
AS A SALT, ESTER OR DERIVATIVE OF THE ENTITY	2	2

(1) THERAPEUTIC EQUIVALENCE EVALUATIONS PROVIDED ONLY FOR MULTISOURCE PRODUCTS (I.E., AVAILABLE FROM MORE THAN ONE APPLICANT)

(2) AMINO ACID-CONTAINING PRODUCTS OF VARYING COMPOSITION (SEE PAGE 1-5 OF THE LIST)

APPROVED PRESCRIPTION DRUG PRODUCTS
 DRUG PRODUCT LIST
 CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84

1

ACETAMINOPHEN; CODEINE PHOSPHATE (PAGE 3-1)

CAPSULE; ORAL
ACETAMINOPHEN W/ CODEINE #3
 AA LEMMON 300MG;30MGX
TYLENOL W/ CODEINE NO. 3
 AA MCNEIL PHARM 300MG;30MG

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE
 AA DURAMED PHARMS 300MG;15MGX
 AA 300MG;30MGX
 AA 300MG;60MGX
PAPA-DEINE #3
 AA VANGARD LABS/MMM 300MG;30MGX
PAPA-DEINE #4
 AA VANGARD LABS/MMM 300MG;60MGX

ACETAMINOPHEN; HYDROCODONE BITARTRATE (PAGE 3-2)

TABLET; ORAL
HYCODAPHEN
 AA BF ASCHER 500MG;5MG

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE (PAGE 3-2)

TABLET; ORAL
CODACET
 AA HALSEY DRUG 325MG;5MGX
 /PERCCOET-5/
 PERCCOET

/ACETAMINOPHEN; PHENACETIN; PHENYLPROPANOLAMINE HYDROCHLORIDE;/
/PHENYLTOLOXAMINE CITRATE/ (PAGE 3-2)

(ALL PRODUCTS - SEE SPECIAL NOTE B.)

ALBUMIN, IODINATED, I-131, SERUM (PAGE 3-4)

INJECTABLE; INJECTION
 /RADIOIODINATED SERUM ALBUMIN (HUMAN) TSA I-131/
 /MALLINCKRODT/ 16.7-250 UC1/ML

AMINO ACIDS (PAGE 3-6)

INJECTABLE; INJECTION
 AMINISS 5.2% ESSENTIAL AMINO ACIDS W/ HISTIDINE
 CUTTER-VITRUM 5.2%
 AMINOSYN 3.5% IN PLASTIC CONTAINER
 ABBOTT LABORATORIES 3.5%
 NEOPHAM 6.5%
 CUTTER-VITRUM 6.5%
 > ADD >
 > ADD >

AMINO ACIDS; MAGNESIUM ACETATE; PHOSPHORIC ACID; POTASSIUM ACETATE; SODIUM CHLORIDE (PAGE 3-7)

INJECTABLE; INJECTION
 AMINOSYN 3.5% M IN PLASTIC CONTAINER
 ABBOTT LABORATORIES 3.5%;21MG/100ML;40MG/100ML;
 128MG/100ML;234MG/100ML X
 > ADD >
 > ADD >
 > ADD >

AMINOPHYLLINE (PAGE 3-8)

/LIQUID; ORAL/
 SOLUTION; ORAL
AMINOPHYLLINE
 AA BAY LABORATORIES 105MG/5MLX
 AA ROXANE LABORATORIES 105MG/5MLX

TABLET; ORAL
AMINOPHYLLINE
 BD BARR LABORATORIES 100MGX
 BD 200MGX
 AB VANGARD LABS/MMM 100MGX
 AB 200MGX

AMITRIPTYLINE HYDROCHLORIDE (PAGE 3-9)

TABLET; ORAL
AMITRIPTYLINE HCL
 AB DANBURY PHARMACAL 10MGX
 AB 25MGX
 AB 50MGX
 AB 75MGX
 AB 100MGX
 AB 150MGX
 BP COPLEY PHARM 10MGX
 BP 25MGX
 BP 50MGX
 BP 75MGX
 BP 100MGX
 BP 150MGX

AZURETIN (PAGE 3-18)

*/GRANULE, ORAL/
/DIAGNEX BLUE/
/ER. SQUIBB AND SONS/ /25M/PACKET/*

BACAMPICILLIN HYDROCHLORIDE (PAGE 3-18)

TABLET; ORAL
SPECTROBID
PFIZER LABS/PFIZER 800MGX

BACITRACIN (PAGE 3-18)

OINTMENT; OPHTHALMIC
BACITRACIN
AT PHARMAFAIR 500 UNITS/GMX

BENTIROMIDE (PAGE 3-19)

SOLUTION; ORAL
CHYMEX
ADRIA LABORATORIES 500MG/7.5MLX

BENZTHIAZIDE (PAGE 3-20)

TABLET; ORAL
AQUATAG
*/BP/ /CORP. LABORATORIES/ /50MG/
/25MG/
BP REID-PROVIDENT LABS 50MG
25MG
/PROQUA/
/BP/ /REID-PROVIDENT LABS/ /50MG/*

BENZTROPINE MESYLATE (PAGE 3-20)

TABLET; ORAL
BENZTROPINE MESYLATE
BP QUANTUM PHARMICS 0.5MGX
BP 1MGX
BP 2MGX
COGENTIN
BP MS&D/MERCK 0.5MG
BP 1MG
BP 2MG

BETAMETHASONE VALERATE (PAGE 3-21)

CREAM; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASEX
AB PHARMADERM/BYK-GLDN EQ 0.1% BASEX
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASEX

LOTION; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASEX
AB PHARMADERM/BYK-GLDN EQ 0.1% BASEX
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASEX
VALISONE
AB SCHERING EQ 0.1% BASE

OINTMENT; TOPICAL

BETAMETHASONE VALERATE
AB E FOUGERA/BYK-GLDN EQ 0.1% BASEX
AB PHARMADERM/BYK-GLDN EQ 0.1% BASEX
BETATREX
AB SAVAGE LABS/BYK-GLDN EQ 0.1% BASEX
VALISONE
AB SCHERING EQ 0.1% BASE

BETHANECHOL CHLORIDE (PAGE 3-21)

TABLET; ORAL
BETHANECHOL CHLORIDE
> ADD > AA SIDMAK LABORATORIES 10MGX
> ADD > AA 25MGX

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE
(PAGE 3-22)

SYRUP; ORAL
AMBENYL
MARION LABORATORIES 12.5MG/5ML;10MG/5ML

BROMPHENIRAMINE MALEATE (PAGE 3-22)

TABLET; ORAL
BROMPHENIRAMINE MALEATE
/AA/ /BOLAR PHARMACEUTICAL/ 4MG/

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE;
PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-23)

SYRUP; ORAL
DIMETANE-DC
AH ROBINS 2MG/5ML;10MG/5ML;12.5MG/5ML

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE (PAGE 3-23)

SYRUP; ORAL
DIMETANE-DX
AH ROBINS
2MG/5ML;10MG/5ML;30MG/5ML

TABLET; ORAL
/SOMA COMPOUND N. CODEINE
/MALLACE PHARMS/C-M / 15MG;30MG;50MG;100MG;150MG

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE (PAGE 3-23)

ELIXIR; ORAL
AH ROBINS
4MG/5ML;25MG/5ML

CAFFEINE; ERGOTAMINE TARTRATE (PAGE 3-25)

SUPPOSITORY; RECTAL
CAFERGOT
BR SANDOZ PHARMS/SANDOZ 100MG;2MG
BR ORGANON/AKZONA 100MG;2MG

TABLET, CONTROLLED RELEASE; ORAL

AH ROBINS
12MG;75MG

BUPIVACAINE HYDROCHLORIDE; DEXTROSE (PAGE 3-23)

> ADD >
> ADD >
> ADD >
INJECTABLE; INJECTION
MARCINE SPINAL
BREON LABS/STERLING 0.75%;8.25%
> ADD >

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE (PAGE 3-23)

INJECTABLE; INJECTION
MARCINE HCL W/ EPINEPHRINE
BREON LABS/STERLING 0.5%;0.0021MG/ML
0.75%;0.0021MG/ML
0.5%;0.0021MG/ML
ASTRA HOSP PHARM 0.5%;0.0021MG/ML
0.75%;0.0021MG/ML

BUTABARBITAL SODIUM (PAGE 3-24)

CAPSULE; ORAL
BUTICAPS

/MCNEIL LABORATORIES//15MG/
/30MG/
/50MG/
/100MG/
MALLACE LABS/C-M

15MG
30MG
50MG
100MG

ELIXIR; ORAL
/BUTABARBITAL SODIUM/
/WEST-MARK/
BUTALAN

/AA/
/AA/
LANNETT
/33.3MG/5ML/
33.3MG/5ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE 30% IN PLASTIC CONTAINER
AM MCGAM/AM HOSP
510MG/100ML;30GM/100ML;
200MG/100ML;9.2GM/100ML;
9.6GM/100ML

DIALYTE CONCENTRATE W/ DEXTROSE 50% IN PLASTIC CONTAINER
AM MCGAM/AM HOSP
510MG/100ML;50GM/100ML
200MG/100ML;9.4GM/100ML;
11GM/100ML

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE (PAGE 3-26)

SOLUTION; INTRAPERITONEAL
DIALYTE W/ DEXTROSE 2.5% IN PLASTIC CONTAINER
AM MCGAM/AM HOSP
26MG/100ML;2.5GM/100ML;
15MG/100ML;560MG/100ML;390MG/100ML

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
SODIUM ACETATE; SODIUM CHLORIDE; SODIUM CITRATE (PAGE 3-27)

INJECTABLE; INJECTION
ISOLYTE E IN PLASTIC CONTAINER
AM MCGAW/AM HOSP 35MG/100ML;30MG/100ML;
74MG/100ML;640MG/100ML;
500MG/100ML;74MG/100MLM

> ADD > CEFONICID SODIUM (PAGE 3-30)

> ADD > INJECTABLE; INJECTION
> ADD > MONOCID
> ADD > SK&F LABORATORIES EQ 500MG BASE/VIALM
> ADD > EQ 1GM BASE/VIALM
> ADD > EQ 2GM BASE/VIALM
> ADD > EQ 10GM BASE/VIALM

> ADD > CEFORANIDE (PAGE 3-30)

> ADD > INJECTABLE; INJECTION
> ADD > PRECEF
> ADD > BRISTOL LABS/B-M 500MG/VIALM
> ADD > 1GM/VIALM
> ADD > 2GM/VIALM
> ADD > 10GM/VIALM
> ADD > 20GM/VIALM

CEFTIZOXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
CEFIZOX
SK&F LABORATORIES EQ 1GM BASE/VIALM
EQ 2GM BASE/VIALM

CEFUROXIME SODIUM (PAGE 3-30)

INJECTABLE; INJECTION
ZINACEF
GLAXO EQ 750MG BASE/VIALM
EQ 1.5GM BASE/VIALM

CELLULOSE SODIUM PHOSPHATE (PAGE 3-30)

POWDER; ORAL
CALCIBIND
MISSION PHARMACAL 2.5GM/PACKET

CEPHALOTHIN SODIUM (PAGE 3-31)

INJECTABLE; INJECTION
> ADD > CEPHALOTHIN SODIUM
> ADD > AP BRISTOL LABS/B-M EQ 1GM BASE/VIALM
> ADD > AP EQ 2GM BASE/VIALM
> ADD > AP EQ 4GM BASE/VIALM

KEFLIN
AP ELI LILLY EQ 1GM BASE/VIAL
AP EQ 2GM BASE/VIAL
> ADD > AP EQ 4GM BASE/VIAL

SEFFIN
AP GLAXO EQ 1GM BASE/VIALM
AP EQ 2GM BASE/VIALM
EQ 10GM BASE/VIALM

CEPHALOTHIN SODIUM; DEXTROSE (PAGE 3-31)

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
TRAVENOL LABS EQ 20MG BASE/ML;50MG/MLM
EQ 40MG BASE/ML;50MG/MLM

CEPHALOTHIN SODIUM; SODIUM CHLORIDE (PAGE 3-31)

INJECTABLE; INJECTION
CEPHALOTHIN SODIUM IN PLASTIC CONTAINER
TRAVENOL LABS EQ 20MG BASE/ML;9MG/MLM
EQ 40MG BASE/ML;9MG/MLM

CHLORDIAZEPOXIDE (PAGE 3-33)

CAPSULE, CONTROLLED RELEASE; ORAL
LIBRELEASE
HOFFMANN-LA ROCHE 30MGM

CHLORDIAZEPOXIDE HYDROCHLORIDE (PAGE 3-33)

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /BOOTS PHARMACEUTICAL/ 5MG/
/AB/ / /10MG/
/AB/ / /25MG/

CHLOROPROCAINE HYDROCHLORIDE (PAGE 3-34)

INJECTABLE; INJECTION
NESACAINE
/PENNALT PHARM /12/
/22/

CORTICOTROPIN (PAGE 3-43)

INJECTABLE; INJECTION
REPOSITORY CORTICOTROPIN
 /BC/ /WYETH LABS/AMMO/ /40 UNITS/ML/
 /BC/ /WYETH LABS/AMMO/ /80 UNITS/ML/

CYANOCOBALAMIN (PAGE 3-44)

INJECTABLE; INJECTION
CYANOCOBALAMIN
 AP SOLOPAK/MPL 1MG/MLX
DODECAMIN
 AP MAURRY BIOLOGICAL 1MG/MLX
REDISOL
 /AP/ MS&D/MERCK /0.1MG/ML/
SYTOBEX
 /AP/ PARKE DAVIS/W-L /0.1MG/ML/

TABLET; ORAL
REDISOL
 > DLT > /MS&D/MERCK/ /0.5MG/
 > DLT >

CYCLOSPORINE (PAGE 3-46)

INJECTABLE; INJECTION
SANDIMMUNE
 SANDOZ PHARMS/SANDOZ 50MG/MLX

SOLUTION; ORAL
SANDIMMUNE
 SANDOZ PHARMS/SANDOZ 100MG/MLX

CYPROHEPTADINE HYDROCHLORIDE (PAGE 3-46)

TABLET; ORAL
CYPROHEPTADINE HCL
 AA DURAMED PHARMS 4MGX
 AA PIONEER PHARMS 4MGX

DAPSONE (PAGE 3-47)

TABLET; ORAL
ACLOSULFON
 /BP/ /AYERST LABS/AMMO/ /25MG/
 /BP/ /AYERST LABS/AMMO/ /100MG/
DAPSONE
 /BP/ JACOBUS PHARM 25MG
 /BP/ 100MG

DESMOPRESSIN ACETATE (PAGE 3-48)

INJECTABLE; INJECTION
DDAVP
 ARMOUR PHARM 0.004MG/MLX

DESOXIMETASONE (PAGE 3-49)

OINTMENT; TOPICAL
TOPICORT
 HOECHST-ROUSSEL 0.25%
 0.25%
 0.25%

DEXAMETHASONE (PAGE 3-49)

SOLUTION; ORAL
DEXAMETHASONE
 ROXANE LABORATORIES 0.5MG/5MLX
 DEXAMETHASONE INTENSOL
 ROXANE LABORATORIES 0.5MG/0.5MLX

TABLET; ORAL
DECADRON
 BP MS&D/MERCK 6MG
DEXAMETHASONE
 /BP/ /MYLAN PHARMS/ /0.75MG/
 BP PAR PHARMACEUTICAL 6MGX
 BP ROXANE LABORATORIES 6MGX
 1MGX

DEXAMETHASONE SODIUM PHOSPHATE (PAGE 3-50)

INJECTABLE; INJECTION
DEXAMETHASONE
 AP INVENEX LABS/DEXTER EQ 4MG PHOSPHATE/MLX
 AP EQ 10MG PHOSPHATE/MLX
DEXAMETHASONE SODIUM PHOSPHATE
 AP INTL MEDICATION SYS EQ 20MG PHOSPHATE/MLX
HEXADROL PHOSPHATE
 /HEXADROL PHOSPHATE/
HEXADROL
 AP ORGANON/AKZONA EQ 4MG PHOSPHATE/ML
 AP EQ 20MG PHOSPHATE/ML

SOLUTION/DROPS; OPHTHALMIC

DEXAIR
 AT PHARMAFAIR EQ 0.1% PHOSPHATEX
DEXAMETHASONE SODIUM PHOSPHATE
 AT BARNES-HIND PHARMS EQ 0.1% PHOSPHATE

DEXCHLORPHENIRAMINE MALEATE (PAGE 3-51)

AA	BAY LABORATORIES	2MG/5ML
AA	SCHERING	2MG/5ML

DEXTRORHOPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-52)

SYRUP; ORAL	PHENERGAN W/ DEXTRORHOPHAN	15MG/5ML; 6.25MG/5ML
MYETH LABS/AMHO		

DEXTROSE; DOPAMINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION	/DOPAMINE HCL IN DEXTROSE 5% /	
AP	DOPAMINE HCL	
AP	ABBOTT LABORATORIES	5GM/100ML; 80MG/100ML
AP	ABBOTT LABORATORIES	5GM/100ML; 160MG/100ML
AP	ABBOTT LABORATORIES	5GM/100ML; 80MG/100ML
AP	ABBOTT LABORATORIES	5GM/100ML; 160MG/100ML
AP	ABBOTT LABORATORIES	5GM/100ML; 320MG/100ML

DEXTROSE; HEPARIN SODIUM (PAGE 3-53)

INJECTABLE; INJECTION	HEPARIN SODIUM 20,000 UNITS AND DEXTROSE 5% IN PLASTIC CONTAINER	
TRAVENOL LABS		
5GM/100ML; 4,000 UNITS/100ML		

DEXTROSE; LIDOCAINE HYDROCHLORIDE (PAGE 3-53)

INJECTABLE; INJECTION	LIDOCAINE HCL 0.2% AND DEXTROSE 5% IN PLASTIC CONTAINER	
AM MCGAM/AM HOSP		
5GM/100ML; 200MG/100ML		
AP	LIDOCAINE HCL 0.4% AND DEXTROSE 5% IN PLASTIC CONTAINER	
AM MCGAM/AM HOSP		
5GM/100ML; 400MG/100ML		
AP	LIDOCAINE HCL 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER	
AM MCGAM/AM HOSP		
5GM/100ML; 800MG/100ML		

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM (PAGE 3-57)

INJECTABLE; INJECTION	/DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM /
DIATRIZOATE-60	

DIETHYLPROPION HYDROCHLORIDE (PAGE 3-59)

SYRUP; ORAL	DIETHYLPROPION HCL	25MG
AA	CAMALL	

DIMENHYDRINATE (PAGE 3-60)

INJECTABLE; INJECTION	DIMENHYDRINATE	50MG/ML
/AB /	/INTL MEDICATION SYS /	

DIPIHENHYDRAMINE HYDROCHLORIDE (PAGE 3-61)

CAPSULE; ORAL	SK-DIPHENHYDRAMINE	75MG
/AA /	SKF LABORATORIES	

ELIXIR; ORAL

AA	HALSEY DRUG	12.5MG/5ML
AA	DIBENIL	

AA	HR CENCI LABS	12.5MG/5ML
AA	DIPHENHYDRAMINE HCL	

/AA /	/CORP LABORATORIES /	/12.5MG/5ML /
/AA /	/SK-DIPHENHYDRAMINE /	

/AA /	/SKF LABORATORIES /	/12.5MG/5ML /
-------	---------------------	---------------

DISULFIRAM (PAGE 3-63)

TABLET; ORAL	DISULFIRAM	
CHELSEA LABORATORIES		250MG
BX		
CHELSEA LABORATORIES		500MG
BX		
SIDMAK LABORATORIES		250MG
BX		
SIDMAK LABORATORIES		500MG
BX		

DOXYCYCLINE HYCLATE (PAGE 3-64)

CAPSULE; ORAL	DOXYCYCLINE HYCLATE	
CHELSEA LABORATORIES		50MG BASE
EA		
HEATHER DRUG		50MG BASE
EA		
CHELSEA LABORATORIES		100MG BASE
EA		
PAR PHARMACEUTICAL		100MG BASE
EA		
PURPAC/KALIPHARMA		50MG BASE
EA		
PURPAC/KALIPHARMA		100MG BASE
EA		
PURPAC/KALIPHARMA		100MG BASE
EA		
WEST-WARD		100MG BASE

DOXYCYCLINE HYCLATE (PAGE 3-64)

INJECTABLE; INJECTION
DOXY 100
 AP LYPHO-MED EQ 100MG BASE/VIALM
DOXY 200
 AP LYPHO-MED EQ 200MG BASE/VIALM
DOXYCYCLINE
 AP ELKINS-SINN EQ 100MG BASE/VIALM
 AP EQ 200MG BASE/VIALM
VIBRAMYCIN
 AP PFIZER LABS/PFIZER EQ 200MG BASE/VIAL

TABLET; ORAL
DOXYCYCLINE HYCLATE
 AB HEATHER DRUG EQ 100MG BASEM

DROPERIDOL; FENTANYL CITRATE (PAGE 3-64)

INJECTABLE; INJECTION
 INNOVAR
 /JANSSEN PHARMA/ 1.25MG/ML; 0.05MG/ML
 JANSSEN PHARMA 2.5MG/ML; EQ 0.05MG BASE/ML

DYCLONINE HYDROCHLORIDE (PAGE 3-64)

SOLUTION; TOPICAL
 DYCLONE
 /MÉRRELL DOW/DOW CHEM/ 0.5%
 /1%/
 ASTRA PHARM PRODS 0.5%
1%

ECHOTHIOPHATE IODIDE (PAGE 3-65)

POWDER FOR RECONSTITUTION; OPHTHALMIC
/échothiopate/
 /AT/ /ALCON LABORATORIES/ 0.03%
 /AT/ 0.06%
 /AT/ 0.125%
 /AT/ 0.25%
 PHOSPHOLINE IODIDE
 /AT/ AYERST LABS/AMHO 0.03%
 /AT/ 0.06%
 /AT/ 0.125%
 /AT/ 0.25%

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE (PAGE 3-66)

INJECTABLE; INJECTION
LIDOCATON
 AP PHARMATON/SZ 0.01MG/ML; 2%
 AP 0.02MG/ML; 2%

ERGOLOID MESYLATES (PAGE 3-66)

CAPSULE; ORAL
/HYDERGINE/
 HYDERGINE LC

TABLET; ORAL
ERGOLOID MESYLATES
 AB CHELSEA LABORATORIES 1MGM

ERYTHROMYCIN (PAGE 3-67)

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
 AT E FOUGERA/BYK-GLDN 5MG/GMM
 AT PHARMADERM/BYK-GLDN 5MG/GMM
 AT PHARMAFAIR 5MG/GMM
ILOTYCIN
 AT DISTA PRODS/LILLY 5MG/GM

ESTRADIOL (PAGE 3-69)

CREAM; VAGINAL
 ESTRACE
 MEAD JOHNSON/B-M 0.01%M

ESTROGENS, CONJUGATED (PAGE 3-70)

TABLET; ORAL
 PREMARIN
 AYERST LABS/AMHO 0.9MGM
 > ADD >

ETHINYL ESTRADIOL; NORETHINDRONE (PAGE 3-72)

TABLET; ORAL-21
 ORTHO-NOVUM 7/14-21
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG AND 1MGM
 ORTHO-NOVUM 7/7/7-21
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG, 0.75MG AND 1MGM
 TRI-NORINYL 21-DAY
 SYNTEX (FP) 0.035MG; 0.5MG AND 1MGM
 TABLET; ORAL-28
 ORTHO-NOVUM 7/14-28
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG AND 1MGM
 ORTHO-NOVUM 7/7/7-28
 ORTHO PHARMACEUTICAL 0.035MG; 0.5MG, 0.75MG AND 1MGM
 TRI-NORINYL 28-DAY
 SYNTEX (FP) 0.035MG; 0.5MG AND 1MGM

DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84	DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84	DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84	DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84	DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84	DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 9 / AUGUST '83 - MAY '84
<p>FTOPOSIDE (PAGE 3-74) INJECTABLE: INJECTION VEPESID BRISTOL LABS/B-H 20MG/MLM</p>	<p>FENTANYL CITRATE (PAGE 3-75) INJECTABLE: INJECTION SUBLIMAZE JANSSEN PHARMA/ JANSSEN PHARMA/ EQ 0.05MG BASE/ML</p>	<p>FLUOCINOLONE ACETONIDE (PAGE 3-76) CREAM: TOPICAL FLUOCET NMC LABORATORIES 0.012% 0.0252%</p>	<p>FLUOCINOLONE ACETONIDE (PAGE 3-76) OINTMENT: TOPICAL FLUOCINOLONE ACETONIDE PHARMAFAIR 0.0252%</p>	<p>FLUOXIMESTERONE (PAGE 3-77) TABLET: ORAL FLUOXIMESTERONE BOLAR PHARMACEUTICAL 2MGX 5MGX BP 10MGX BP 10MGX COLMED LABORATORIES 10MGX</p>	<p>FLUOCINONIDE (PAGE 3-76) SOLUTION: TOPICAL LIDEX SYNTEX LABS/SYNTEX 0.052%</p>
<p>GENTAMICIN SULFATE (PAGE 3-79) INJECTABLE: INJECTION FUROSEMIDE NATCON 10MG/MLM</p>	<p>GENTAMICIN SULFATE (PAGE 3-79) CREAM: TOPICAL GENTAFAIR PHARMAFAIR NMC LABORATORIES EQ 1MG BASE/GM</p>	<p>GENTAMICIN SULFATE (PAGE 3-79) INJECTABLE: INJECTION GENTAMICIN SULFATE NMC LABORATORIES EQ 1MG BASE/GM</p>	<p>GENTAMICIN SULFATE (PAGE 3-79) INJECTABLE: INJECTION GENTAMICIN SULFATE ABBOTT LABORATORIES EQ 60MG BASE/100MLM EQ 70MG BASE/100MLM EQ 80MG BASE/100MLM EQ 90MG BASE/100MLM EQ 100MG BASE/100MLM EQ 1.2MG BASE/MLM EQ 1.4MG BASE/MLM EQ 1.6MG BASE/MLM EQ 1.8MG BASE/MLM EQ 2MG BASE/MLM EQ 10MG BASE/MLM EQ 40MG BASE/MLM EQ 40MG BASE/MLM EQ 40MG BASE/MLM LYPHO-MED GENTAMICIN SULFATE IN PLASTIC CONTAINER EQ 60MG BASE/100MLM ABBOTT LABORATORIES</p>	<p>FLUOXIMESTERONE (PAGE 3-77) TABLET: ORAL FLUOXIMESTERONE BOLAR PHARMACEUTICAL 2MGX 5MGX BP 10MGX BP 10MGX COLMED LABORATORIES 10MGX</p>	<p>FLUOXIMESTERONE (PAGE 3-77) TABLET: ORAL FLUOXIMESTERONE BOLAR PHARMACEUTICAL 2MGX 5MGX BP 10MGX BP 10MGX COLMED LABORATORIES 10MGX</p>
<p>FTOPOSIDE (PAGE 3-74) INJECTABLE: INJECTION FUROSEMIDE INVENEX LABS/DEXTER 10MG/MLM</p>	<p>FENTANYL CITRATE (PAGE 3-75) INJECTABLE: INJECTION SUBLIMAZE JANSSEN PHARMA/ JANSSEN PHARMA/ EQ 0.05MG BASE/ML</p>	<p>FLUOCINOLONE ACETONIDE (PAGE 3-76) CREAM: TOPICAL FLUOCET NMC LABORATORIES 0.012% 0.0252%</p>	<p>FLUOCINOLONE ACETONIDE (PAGE 3-76) OINTMENT: TOPICAL FLUOCINOLONE ACETONIDE PHARMAFAIR 0.0252%</p>	<p>FLUOXIMESTERONE (PAGE 3-77) TABLET: ORAL FLUOXIMESTERONE BOLAR PHARMACEUTICAL 2MGX 5MGX BP 10MGX BP 10MGX COLMED LABORATORIES 10MGX</p>	<p>FLUOCINONIDE (PAGE 3-76) SOLUTION: TOPICAL LIDEX SYNTEX LABS/SYNTEX 0.052%</p>

GENTAMICIN SULFATE (PAGE 3-79)

SOLUTION/DROPS; OPHTHALMIC

GENTACIDIN

AT COOPERVISION PHARMS EQ 3MG BASE/MLM

> ADD > GLIPIZIDE (PAGE 3-80)

> ADD > TABLET; ORAL

> ADD > GLUCOTROL

> ADD > ROERIG/PFIZER 5MGM

> ADD > 10MGM

> ADD > GLYBURIDE (PAGE 3-80)

> ADD > TABLET; ORAL

> ADD > DIABETA

> ADD > BX HOECHST-ROUSSEL 1.25MGM

> ADD > BX 2.5MGM

> ADD > BX 5MGM

> ADD > MICRONASE

> ADD > BX UPJOHN 1.25MGM

> ADD > BX 2.5MGM

> ADD > BX 5MGM

GONADOTROPIN, CHORIONIC (PAGE 3-81)

INJECTABLE; INJECTION

ANTUITRIN'S
/AA/ /PARKE-DAVIS/M-L/ /5,000 UNITS/VIAL/

GRISEOFULVIN, ULTRAMICROCRYSTALLINE (PAGE 3-82)

TABLET; ORAL

FULVICIN P/G 165

AB SCHERING 165MG

FULVICIN P/G 330

AB SCHERING 330MG

GRIS-PEG

> DLT > /AB/ /BORSEY LABS/SANDOZ/ /125MG/

> DLT > /AB/ /250MG/

> ADD > AB HERBERT LABS/ALLERGN 125MG

> ADD > AB 250MG

GRISACTIN ULTRA

AB AYERST LABS/AMHO 165MGM

AB 330MGM

HEPARIN SODIUM (PAGE 3-83)

INJECTABLE; INJECTION

HEPARIN SODIUM

AP NATCON CHEMICAL 1,000 UNITS/MLM

HEPARIN SODIUM; SODIUM CHLORIDE - IN PLASTIC (PAGE 3-85)

INJECTABLE; INJECTION

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 10,000 UNITS/100ML;450MG/100MLM

HEPARIN SODIUM 10,000 UNITS IN SODIUM CHLORIDE 0.9%

ABBOTT LABORATORIES 10,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100MLM

HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;450MG/100MLM

AP ABBOTT LABORATORIES 10,000 UNITS/100ML;450MG/100MLM

HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.9%

AP ABBOTT LABORATORIES 5,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.9%

ABBOTT LABORATORIES 1,000 UNITS/100ML;900MG/100MLM

HEPARIN SODIUM 5,000 UNITS IN SODIUM CHLORIDE 0.45%

AP ABBOTT LABORATORIES 100 UNITS/ML;4.5MG/MLM

HOMATROPINE METHYLBROMIDE (PAGE 3-86)

TABLET; ORAL

HOMAPIN-10

/AA/ MISSION PHARMACAL 10MG

/AA/ /SEDS-TENS'SE/

/AA/ /LEMON/ /10MG/

HYDRALAZINE HYDROCHLORIDE (PAGE 3-86)

INJECTABLE; INJECTION

APRESOLINE

AP CIBA/CIBA-GEIGY 20MG/ML

HYDRALAZINE HCL

AP SOLOPAK LABORATORIES 20MG/MLM

TABLET; ORAL

HYDRALAZINE HCL

AA PAR PHARMACEUTICAL 100MGM

AA PUREPAC/KALIPHARMA 50MGM

> ADD > AA 10MGM

> ADD > AA 50MGM

> ADD > AA 100MGM

> ADD > AA 25MGM

> ADD > AA 50MGM

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE (PAGE 3-87)

CAPSULE; ORAL

HYDRALAZINE HCL W/ HYDROCHLOROTHIAZIDE 25/25

AB ZENITH LABORATORIES 25MG;25MGM

HYDROFLUMETHIAZIDE; RESERPINE (PAGE 3-95)

TABLET; ORAL
HYDROFLUMETHIAZIDE AND RESERPINE
BP COLNED LABORATORIES 50MG;0.125MG

HYDROMORPHONE HYDROCHLORIDE (PAGE 3-95)

INJECTABLE; INJECTION
DILAUDID-HP
KNOLL PHARMACEUTICAL 10MG/ML

HYDROXYZINE HYDROCHLORIDE (PAGE 3-96)

TABLET; ORAL
HYDROXYZINE HCL
AB BARR LABORATORIES 10MG
AB DANBURY PHARMACAL 10MG
AB 25MG
AB 50MG

HYDROXYZINE PAMOATE (PAGE 3-96)

CAPSULE; ORAL
HYDROXYZINE PAMOATE
AB DURAMED PHARMS EQ 25MG HCL
AB EQ 50MG HCL
AB EQ 100MG HCL
AB VANGARD LABS/PHM EQ 25MG HCL
AB EQ 50MG HCL

IBUPROFEN (PAGE 3-97)

TABLET; ORAL
MOTRIN
AB UPJOHN MANUFACTURING 600MG
RUFEN
AB BOOTS PHARMACEUTICAL 600MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
/BP/ /ANTIPRESS/
/BP/ /LEMON/ /25MG/
/AB/ /INAVATE/
/AB/ /A.H. ROBINSON/ /25MG/
/AB/ /50MG/
IMIPRAMINE HCL
> ADD > AB GEIGY/CIBA-GEIGY 10MG
> ADD > AB 25MG
> ADD > AB 50MG

IMIPRAMINE HYDROCHLORIDE (PAGE 3-97)

TABLET; ORAL
IMIPRAMINE HCL
AB PAR PHARMACEUTICAL 10MG
AB 25MG
AB 50MG
TOFRANIL
/BP/ /GEIGY/CIBA-GEIGY/ /25MG/
AB GEIGY/CIBA-GEIGY 25MG

INDOMETHACIN (PAGE 3-98)

CAPSULE; ORAL
INDOCIN
AB MS&D/MERCK 25MG
AB 50MG
> ADD > AB INDOMETHACIN
> ADD > AB LEDERLE LABS/AM CYAN 25MG
AB 50MG
AB MYLAN PHARMS 25MG
AB 50MG
> ADD > AB ZENITH LABORATORIES 25MG
> ADD > AB 50MG

ISOETHARINE HYDROCHLORIDE (PAGE 3-100)

SOLUTION; INHALATION
ISOETHARINE HCL
AN ARMOUR PHARM 0.167%
AN 0.2%
AN 0.25%
AN INTL MEDICATION SYS 0.167%
AN ROXANE LABORATORIES 0.167%
AN TRAVENOL LABS 0.14%
AN 0.25%

ISONIAZID (PAGE 3-101)

SYRUP; ORAL
ISONIAZID
AA CAROLINA MED PRODS 50MG/5ML
RIMIFON
AA HOFFMANN-LA ROCHE 50MG/5ML

TABLET; ORAL
> DLT > /RIMIFON/
> DLT > /AA/ /HOFFMANN-LA ROCHE/ /50MG/
> DLT > /AA/ /100MG/

METRONIDAZOLE (PAGE 3-122)

INJECTABLE; INJECTION
METRONIDAZOLE IN PLASTIC CONTAINER
 AP ABBOTT LABORATORIES 50MG/100ML*
METRO I.V. IN PLASTIC CONTAINER
 AP AM MCGAW/AM HOSP 500MG/100ML*

TABLET; ORAL
METRONIDAZOLE
 > ADD > AB CHELSEA LABORATORIES 500MG*
 AB LNK INTERNATIONAL 250MG*
 AB PAR PHARMACEUTICAL 250MG*
 AB 500MG*

NANDROLONE DECANOATE (PAGE 3-125)

INJECTABLE; INJECTION
NANDROLONE DECANOATE
 AQ CARTER-GLOGAU 200MG/ML*
 AQ LEMMON 100MG/ML
 50MG/ML
 AQ LYPHO-MED 100MG/ML*
 AQ 200MG/ML*
 AQ MAURRY BIOLOGICAL 100MG/ML*

NAPHAZOLINE HYDROCHLORIDE (PAGE 3-125)

SOLUTION/DROPS; OPHTHALMIC
VASOCON
 /AT/ /SMP/PR/COOPERVISION/ 0.1%
 AT COOPERVISION PHARMS 0.1%

NEOMYCIN SULFATE; PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-126)

> DLT > /SOLUTION/DROPS; OPHTHALMIC/
 > DLT > /NEO-HYDELTRASOL/
 > DLT > /MS&D/MERCK/ /EQ 3.5MG BASE/ML; EQ 0.5% PHOSPHATE/

NIACIN (PAGE 3-127)

TABLET; ORAL
NIACIN
 /AA/ /NYLAN PHARMS/ /50MG/

NICOTINE RESIN COMPLEX (PAGE 3-127)

GUM, CHEWING; ORAL
NICORETTE
 MERRELL DOW/DOW CHEM EQ 2MG BASEM

NITROGLYCERIN (PAGE 3-128)

INJECTABLE; INJECTION
NITRONAL
 AP G POHL-BOSKAMP 5MG/ML*
 1MG/ML*
NITROSTAT
 AP PARKE-DAVIS/W-L 5MG/ML*
TRIDIL
 AM CRITICAL CARE/AHS 0.5MG/ML*

NYSTATIN (PAGE 3-129)

OINTMENT; TOPICAL
NYSTATIN
 AT CLAY-PARK LABS 100,000 UNITS/GM*

POWDER; ORAL
NILSTAT
 LEDERLE LABS/AM CYAN 100%*

TABLET; ORAL
NYSTATIN
 AA PAR PHARMACEUTICAL 500,000 UNITS*

TABLET; VAGINAL
NYSTATIN
 AT E FOUGERA/BYK-GLDN 100,000 UNITS*
 AT PHARMADERM/BYK-GLDN 100,000 UNITS*
 AT QUANTUM PHARMICS 100,000 UNITS*

OXPRENOLOL HYDROCHLORIDE (PAGE 3-131)

CAPSULE; ORAL
TRASICOR
 CIBA/CIBA-GEIGY 20MG*
 40MG*
 80MG*
 160MG*

OXTRIPHYLLINE (PAGE 3-131)

ELIXIR; ORAL
OXTRIPHYLLINE
 BAY LABORATORIES 100MG/5ML*

SYRUP; ORAL
CHOLEDYL
 AA PARKE-DAVIS/W-L 50MG/5ML
 AA OXTRIPHYLLINE PEDIATRIC
 BAY LABORATORIES 50MG/5ML*

OXTERIPHYLLINE (PAGE 3-131)

ELIXIR; ORAL
 TABLET, ENTERIC COATED; ORAL
 CHOLELYL
 PARKE-DAVIS/M-L 100MG
 200MG
 200MG
 OXTERIPHYLLINE
 BOLAR PHARMACEUTICAL 100MG
 200MG

OXTETRAACYCLINE HYDROCHLORIDE (PAGE 3-132)

CAPSULE; ORAL
 /DOLBAC/
 /AB/ /PARKE-DAVIS/M-L/ /EQ 250MG BASE/

PENICILLIN V POTASSIUM (PAGE 3-135)

POWDER FOR RECONSTITUTION; ORAL
 /UTICLIN VR/
 /AA/ /PPJHN/
 /EQ 125MG BASE/5ML/
 /EQ 250MG BASE/5ML/

PENDIMETRAZINE TARTRATE (PAGE 3-136)

TABLET; ORAL
 PHENDIMETRAZINE TARTRATE
 FERNDALE LABS 35MG

PHENTERMINE HYDROCHLORIDE (PAGE 3-139)

CAPSULE; ORAL
 ADIPEX-P
 LEMON
 DAPEX-37.5
 FERNDALE LABS
 PHENTERMINE HCL
 37.5MG
 37.5MG
 37.5MG

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE (PAGE 3-140)

SYRUP; ORAL
 PHENEGAN VC
 METH LABS/AMHO
 5MG/5ML; 6.25MG/5ML

> ADD >

POTASSIUM CHLORIDE (PAGE 3-143)

CAPSULE, CONTROLLED RELEASE; ORAL
 MICRO-K 10
 AH ROBINS 10MEG

INJECTABLE; INJECTION

POTASSIUM CHLORIDE
 TRAVENOL LABS
 /AB/ /AB/
 /AB/ /AB/
 /AB/ /AB/

PREDNISOLONE (PAGE 3-145)

TABLET; ORAL

PREDNISOLONE
 /BX/ /MYLAN PHARMS/
 /BX/ /KAYAL DRUGS/
 /5MG/ /5MG/

PREDNISOLONE ACETATE (PAGE 3-146)

INJECTABLE; INJECTION

/FERNISOLONE/
 /FERNDALE LABS/
 /BP/ /FMS/M/

PREDNISOLONE SODIUM PHOSPHATE (PAGE 3-147)

SOLUTION/DROPS; OPHTHALMIC

/HYDELTRASOL/
 /MSD/MERCK/
 /EQ 0.5% PHOSPHATE/
 /INFLAMASE/
 /INFLAMASE MILD/
 COOPERVISION PHARMS
 EQ 0.11% PHOSPHATE

INFLAMASE FORTE

/SMF/PR/COOPERVISION/
 /EQ 0.8% BASE/

COOPERVISION PHARMS

EQ 0.9% PHOSPHATE
 METRETION
 SCHERING
 PHARMAFAIR
 PREDAIR

PREDAIR FORTE

PHARMAFAIR
 PREDAIR
 EQ 0.9% PHOSPHATE

BARNES-HIND PHARMS

EQ 0.11% PHOSPHATE
 EQ 0.9% PHOSPHATE
 EQ 0.11% PHOSPHATE
 EQ 0.8% BASE/
 EQ 0.11% PHOSPHATE
 MAURRY BIOLOGICAL
 EQ 0.11% PHOSPHATE
 EQ 0.9% PHOSPHATE
 AI

PREDNISOLONE TEBUTATE (PAGE 3-147)

INJECTABLE; INJECTION
 HYDELTRA-TBA
 BP MS&D/MERCK 20MG/ML
 PREDNISOLONE TEBUTATE
 BP CARTER-GLOGAU LABS 20MG/ML*

PREDNISON (PAGE 3-147)

TABLET; ORAL
 PREDNISON
 BX DURAMED PHARMS 5MG*
 BX 10MG*
 BX 20MG*
 /BX/ /NYLAN PHARMS/ /5MG/

PROBENECID (PAGE 3-149)

TABLET; ORAL
PROBENECID
 > ADD > AB ZENITH LABORATORIES 500MG*

PROCAINAMIDE HYDROCHLORIDE (PAGE 3-149)

CAPSULE; ORAL
PROCAN
 /AB/ PARKE-DAVIS/W-L /250MG/
 /AB/ /500MG/

PROMETHAZINE HYDROCHLORIDE (PAGE 3-152)

SYRUP; ORAL
 /PHENERGAN/
 PHENERGAN PLAIN

PROPANTHELINE BROMIDE (PAGE 3-153)

TABLET; ORAL
PROPANTHELINE BROMIDE
 AA PAR PHARMACEUTICAL 15MG*

PROPOXYPHENE HYDROCHLORIDE (PAGE 3-153)

CAPSULE; ORAL
PROPOXYPHENE HCL
 AA RICHLYN LABORATORIES 65MG

PROPYLTHIOURACIL (PAGE 3-154)

TABLET; ORAL
 PROPYLTHIOURACIL
 /BP/ /NYLAN PHARMS/ /50MG/

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE (PAGE 3-155)

SYRUP; ORAL
ACTANIST
 AA HR CENCI LABS 30MG/5ML; 1.25MG/5ML*
HISTAFED
 AA LIFE LABORATORIES 30MG/5ML; 1.25MG/5ML*
 /PSEUDOEPHEDRINE/
 /AA/ /BAY LABORATORIES/ /30MG/5ML; 1.25MG/5ML/
 /TRIACTIN/
 /AA/ /NATL PHARM MFG/BARRE/ 30MG/5ML; 1.25MG/5ML/
TRIPROSED
 AA HALSEY DRUG 30MG/5ML; 1.25MG/5ML*

TABLET; ORAL
 /TRI-SUDO/
 /AA/ /MD PHARMACEUTICAL/ /60MG; 2.5MG*/
 /TRIPRODRINE/
 /AA/ /DANBURY PHARMACAL/ /60MG; 2.5MG/
TRIPROLIDINE AND PSEUDOEPHEDRINE
 AA BOLAR PHARMACEUTICAL 60MG; 2.5MG*
 /AA/ /WEST-WARD/ /60MG; 2.5MG/
TRIPROLIDINE HCL AND PSEUDOEPHEDRINE HCL
 AA CHELSEA LABORATORIES 60MG; 2.5MG*

QUINIDINE GLUCONATE (PAGE 3-157)

TABLET, CONTROLLED RELEASE; ORAL
QUINIDINE GLUCONATE
 AB ROXANE LABORATORIES 324MG*

QUINIDINE SULFATE (PAGE 3-157)

TABLET; ORAL
QUINIDINE SULFATE
 AB VITARINE/WEST CHEM 300MG*

RAUMOLFIA SERPENTINA (PAGE 3-158)

TABLET; ORAL
 RAUMOLFIA SERPENTINA
 > DLT > /BP/ /KIRKMAN LABORATORIES/ 50MG/
 > DLT > /BP/ /100MG/

SULFINPYRAZONE (PAGE 3-169)

CAPSULE; ORAL
SULFINPYRAZONE
 AB VANGARD LABS/MMM 200MG

SULFISOXAZOLE (PAGE 3-170)

/CREAM; VAGINAL/
 /GANTRISIN/
 /AT/ /HOFFMANN-LA ROCHE/ /10%/
 /AT/ /KORO-SULE/
 /AT/ /HOLLAND-RANTOS/ /10%/
 /AT/ /MYLAN PHARMS/ /500MG/

TABLET; ORAL
SULFISOXAZOLE
 /AT/ /MYLAN PHARMS/ /500MG/

TERBUTALINE SULFATE (PAGE 3-173)

TABLET; ORAL
 BRICANYL
 /BP/ /ASTRA PHARM PRODS/ /2.5MG/
 /BP/ /5MG/
 BP MERRELL DOW/DOW CHEM 2.5MG
 BP 5MG

TESTOSTERONE (PAGE 3-173)

INJECTABLE; INJECTION
 TESTOSTERONE
 CARTER-GLOGAU LABS 50MG/ML

TETRACYCLINE HYDROCHLORIDE (PAGE 3-174)

CAPSULE; ORAL
TETRACYCLINE HCL
 /AB/ /LEMON/ /250MG/

TABLET; ORAL
PANMYCIN
 /AB/ UPJOHN /250MG/
SUMYCIN
 /AB/ ER SQUIBB AND SONS 250MG

THALLOUS CHLORIDE, TL-201 (PAGE 3-175)

INJECTABLE; INJECTION
THALLOUS CHLORIDE TL 201
 MEDI-PHYSICS 2MCI/ML

THEOPHYLLINE (PAGE 3-176)

(FOR CONTROLLED RELEASE PRODUCTS - SEE SPECIAL NOTE C.)

CAPSULE, CONTROLLED RELEASE; ORAL
 SOMOPHYLLIN-CRT
 BC FISONS 100MG
 THEO-24
 BC SEARLE/SEARLE PHARMS 100MG
 200MG
 300MG

ELIXIR; ORAL
ELIXOMEN
 AA HR CENCI LABS 80MG/15ML

SOLUTION; ORAL
THEOLAIR
 AA RIKER LABS/3M 80MG/15ML
THEOPHYLLINE
 AA ROXANE LABORATORIES 80MG/15ML

TABLET, CONTROLLED RELEASE; ORAL
 THEOCONTIN
 BC PURDUE FREDERICK 200MG
 /400MG/
THEO-DUR
 BC KEY PHARMACEUTICALS 200MG
 UNIPHYL
 PURDUE FREDERICK 400MG

THIORIDAZINE HYDROCHLORIDE (PAGE 3-178)

CONCENTRATE; ORAL
THIORIDAZINE HCL
 AA CORD LABORATORIES 30MG/ML
 AA 100MG/ML
 AA NATL PHARM MFG/BARRE 100MG/ML

TABLET; ORAL
MELLARIL
 AB SANDOZ PHARMS/SANDOZ 100MG
 AB 150MG
 AB 200MG
THIORIDAZINE HCL
 AB BARR LABORATORIES 10MG
 AB 15MG
 AB 25MG
 AB 50MG
 AB 100MG
 AB BOLAR PHARMACEUTICAL 10MG
 AB 100MG
 AB 150MG
 AB 200MG

TRIAMCINOLONE ACETONIDE (PAGE 3-180)

CREAM; TOPICAL
 TRIAMCINOLONE ACETONIDE
 BAY LABORATORIES 0.025%
 AT 0.1%
 AT 0.5%
 TRIDERM
 DEL-RAY LABORATORIES 0.1%
 AT 0.1%
 AT 0.5%
 ONTMENT; TOPICAL
 TRIAMCINOLONE ACETONIDE
 BAY LABORATORIES 0.025%
 AT 0.1%
 AT 0.5%

TRIFLUOPERAZINE HYDROCHLORIDE (PAGE 3-183)

TABLET; ORAL
 /TRIAZINE/
 TFP

TRIPLENNAMINE HYDROCHLORIDE (PAGE 3-185)

TABLET; ORAL
 TRIPLENNAMINE HCL
 /WEST-WARD/
 /50MG/

TRISULFAPYRIMIDINES (PAGE 3-185)

SUSPENSION; ORAL
 /SUAD-KANDID/
 /ELDER PHARMS/
 /TRISUL/
 /BEECHAM LABS/BEECHAM/500MG/5ML
 /TRISUL/
 /REID-PROVIDENT LABS/500MG/5ML

TABLET; ORAL
 /SUADNETTS/
 /ELDER PHARMS/
 /TRIPLE SULFA 2/
 /ZENITH LABORATORIES/500MG/

TROPICAMIDE (PAGE 3-186)

SOLUTION/DROPS; OPHTHALMIC
 HYDRAFAIR
 PHARMAFAIR
 AT 0.5%
 AT 1%

THIORIAZINE HYDROCHLORIDE (PAGE 3-178)

TABLET; ORAL
 THIORIAZINE HCL
 CHELSEA LABORATORIES 10MG
 < ADD >
 15MG
 < ADD >
 25MG
 < ADD >
 50MG
 < ADD >
 100MG
 CORD LABORATORIES
 10MG
 15MG
 25MG
 50MG
 DANBURY PHARMACAL
 10MG
 15MG
 25MG
 50MG
 MYLAN PHARMS
 100MG
 10MG
 50MG
 ROXANE LABORATORIES
 10MG
 15MG
 25MG
 50MG
 WEST-WARD
 10MG
 15MG
 25MG
 50MG
 ZENITH LABORATORIES
 100MG
 50MG
 25MG
 15MG
 10MG

TABLET; ORAL
 BLOCADREN
 MSD/MERCK
 5MG
 TRIAMCINOLONE (PAGE 3-180)
 TABLET; ORAL
 TRIAMCINOLONE
 MYLAN PHARMS
 /5MG/
 /5MG/

TIMOLOL MALEATE (PAGE 3-179)

AEROSOL; INHALATION
 /ARISTOCORT/
 /LEPREF LABS/AN/CYAN/0.25MG/INH/
 AZMACORT
 WILLIAM H RORER
 0.25MG/INH

/TYBAMATE/ (PAGE 3-186)

/CAPSULE; ORAL/
/TYBATRAN/
/A.H. ROBIN/ /150MG/
 /350MG/

VECURONIUM BROMIDE (PAGE 3-187)

INJECTABLE; INJECTION
 NORCURON (NC-45)
 ORGANON/AKZONA 10MG/VIALx

VERAPAMIL HYDROCHLORIDE (PAGE 3-187)

INJECTABLE; INJECTION
CALAN
AP SEARLE PHARMS 2.5MG/MLx
ISOPTIN
AP KNOLL PHARMACEUTICAL 2.5MG/ML

VITAMIN A PALMITATE (PAGE 3-188)

CAPSULE; ORAL
/SOLVISTYN A/
/AA/ /TOWNE, PAULSEN/ /EQ 50,000 UNITS BASE/

WATER FOR INJECTION, STERILE (PAGE 3-189)

LIQUID; N/A
STERILE WATER FOR INJECTION IN PLASTIC CONTAINER
AP AM MCGAW/AM HOSP 100%x
AP INVENEX LABS/DEXTER 100%x

/TRANYLCYPROMINE SULFATE/ (PAGE AD9)

/TABLET; ORAL/

/PARNATE/

/SK&F LABORATORIES/ /EQ LONG BASE/

